Ranked 14th among nearly 5,000 hospitals by U.S. News & World Report, Mount Sinai Medical Center is a recognized leader for unrivaled clinical care, innovation and research, and is at the forefront of shaping the healthcare landscape. The Icahn School of Medicine at Mount Sinai, ranked 18th nationwide, is driven by a culture of advancing scholarly inquiry to stimulate collaboration among scientists and physicians with the goal of elevating personalized clinical care.
Mount Sinai is advancing this mission through its state-of-the-art technology and dedicated research institutes. At the Charles Bronfman Institute for Personalized Medicine, our investigators are accelerating genetics and genomics research through the use of DNA, molecules, biomarkers, and personal health information. This team works closely with our Department of Pathology and Institute for Genomics and Multiscale Biology – all of which utilize our BioBank’s collection of DNA and plasma samples from more than 23,000 individuals.
Recently the School of Medicine unveiled its new supercomputer to help researchers unlock the intricate mechanisms that drive human diseases and hasten the discovery of new treatments. Named ‘Minerva’ after the Roman goddess of wisdom, this powerful data processing source provides 64 million hours of computation each year. It features 7,680 processing cores, a peak speed of 70,000 gigaflops and 30 terabytes of random access memory, making it one of the nation’s highest-performing computers in academic medicine.
The computer’s ability to provide researchers with real-time computation of advanced molecular models and a quick analysis of genomic patterns will help Mount Sinai usher in this new era of personalized and precision medicine. It also analyzes data from the Biobank, and our collective teams use Minerva extensively to build predictive models and stratify patients into treatment groups.
These vast resources have positioned Mount Sinai to redefine the science of genetics and pathology toward one that can potentially thwart disease with early treatments. Such innovations will allow patients to bypass unnecessary tests and enable physicians to determine – at the cellular level – the most precise therapies, based upon each patient’s unique genetic fingerprint.